|Bid||0.3500 x N/A|
|Ask||0.3550 x N/A|
|Day's Range||0.3500 - 0.3550|
|52 Week Range||0.1200 - 0.7100|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Vancouver, Canada, and Rehovot, Israel--(Newsfile Corp. - October 13, 2021) - BioHarvest Sciences Inc. (CSE: BHSC) (FSE: 8MV) ("BioHarvest" or the "Company") today announces an update to its forecast of 2021 annual sales orders for VINIA® in Israel. The Company has increased its 2021 sales orders forecast for Israel to US$ 1.6M - US$ 1.7M from the previous forecast of US$ 1.3M - US$ 1.5M announced in March 2021. The continued adoption of VINIA® ...
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - October 12, 2021) - BioHarvest Sciences Inc. (CSE: BHSC) (FSE: 8MV) ("BioHarvest" or the "Company") invites its shareholders and the general public to join a Live Video Conference ("Webinar") on Thursday, October 14, 2021, at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time).BioHarvest Sciences CEO Ilan Sobel will host the event, which will include a report on all major 2021 priorities, including a detailed performan
BioHarvest Sciences Inc. ("BioHarvest" or the "Company") (CSE: BHSC) today announced another strong quarter, fueled by strong growth of VINIA® sales in Israel and the U.S. Q3 VINIA® pilot sales revenues were USD 688K representing 44% growth over Q2 2021 and 1,198% growth over Q3 2020.